Iceland· IS-EU/1/19/1414/003 & 005-006
Mayzent
A siponimod product containing siponimodum inn fúmarsýra, registered in Iceland by Novartis Europharm Limited*. The same ATC class is registered in 12 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Siponimod is registered in 12 of 19 countries.
Countries holding a registration under ATC L04AE03 (siponimod), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 8 of them publish a price we can compare per daily dose
Siponimod · ATC L04AE03
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Italyprice
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of siponimod costs, country by country.
Normalised to the WHO defined daily dose (2 mg), so markets compare like for like.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Siponimod · price per daily dose (2 mg)
USD · FX 28 Sept 2026
- IT Italy$120.54
- CH Switzerland$118.82
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Siponimodum INN fúmarsýra
- Manufacturer
- Novartis Europharm Limited*
- Country
- Iceland (IS)
- ATC code
- L04AE03
- ATC class
- Siponimod
- Defined daily dose
- 2 mg, O
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 1
1 priced- ean41492128 stk x1 þpakkiISK 272694
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
667 interactions on record for siponimod.
Graded by severity as the source publishes them — 597 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Siponimod · interactions on record
667 records
- 597 severe
- 66 moderate
- 4 minor
Most severe, free to view
- CimetidineA02BA01severe
- RanitidineA02BA02severe
- FamotidineA02BA03severe
- NizatidineA02BA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Siponimod in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesMAYZENTNovartis Pharmaceuticals Corporation
- SpainMAYZENT 2 MG COMPRIMIDOS RECUBIERTOS CON PELICULANovartis Europharm Limited
- FinlandMayzentNovartis Europharm Limited
- SwitzerlandMayzent 2.00 mg, FilmtablettenNovartis Pharma Schweiz AG
- PolandMayzentNovartis Europharm Limited
- SwedenMayzent 2 mg Filmdragerad tablettNovartis Europharm Limited
- NetherlandsMayzent 2 mg, filmomhulde tablettenNovartis Europharm Limited
- United KingdomMayzent 0.25mg tabletsNovartis Pharmaceuticals UK Ltd
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Mayzent
- Norway · Mayzent
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/1f803cff-fb9d-4c1e-b9ab-1c0282ab4e7a GET /v1/drugs/1f803cff-fb9d-4c1e-b9ab-1c0282ab4e7a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmuhúðuð tafla",
"source": "lyfjastofnun",
"atc_raw": "L04AE03",
"marketed": true,
"strength": "2 mg",
"ma_number": "EU/1/19/1414/003 & 005-006",
"substance": "Siponimodum INN fúmarsýra",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í taugasjúkdómum með sérþekkingu og reynslu í meðferð á MS.\r\nMarkaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "43843"
}See everything about siponimod.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.